Daprodustat - Latest Advances

Hepcidin and Cardiovascular Events in CKD With and Without Dialysis.

Journal: Kidney international reports

Published: June 15, 2026

Daprodustat augments red cell and γ-globin production in models of sickle cell disease.

Journal: Blood. Red cells & iron

Published: June 10, 2026

LC-PDA & LC-MS/MS approach of Daprodustat: forced degradation study.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: June 05, 2026

Detection and confirmation of hypoxia-inducible factor activating agents in equine plasma and urine by liquid chromatography coupled to mass spectrometry.

Journal: Journal of chromatography. A

Published: May 05, 2026

Association Between Perioperative Daprodustat Use and Early Posttransplant Graft Function in Living Donor Kidney Transplantation: A Propensity Score-Matched Retrospective Study.

Journal: Current therapeutic research, clinical and experimental

Published: April 19, 2026

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan.

Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

Published: April 17, 2026

Hypoxia inducible factors regulate pneumovirus replication by enhancing innate immune sensing.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 07, 2026

Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis.

Journal: Renal failure

Published: February 03, 2026

Association of nutritional indices with hyporesponsiveness to hypoxia-inducible factor-prolyl hydroxylase inhibitors in patients with chronic kidney disease: a single-center retrospective observational study.

Journal: BMC nephrology

Published: January 15, 2026

Prolyl hydroxylase inhibitors, roxadustat and daprodustat, inhibit platelet activation and thrombosis through the PI3K/AKT/HIF-1α pathway.

Journal: Biochemical pharmacology

Published: November 29, 2025

Daprodustat in heart failure and renal anemia: Still early, but promising.

Journal: Journal of cardiology

Published: October 13, 2025

Structure-Based Optimization of HIF-2α Agonists That Synergistically Enhance Erythropoietin Production with PHD Inhibitors.

Journal: Journal of medicinal chemistry

Published: October 06, 2025